Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 8/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.52 |
| ▸ | HPGD | P15428 | 7/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 6/20 | 0.52 |
| ▸ | GAA | P10253 | 2/20 | 0.50 |
| ▸ | USP2 | O75604 | 1/20 | 0.46 |
| ▸ | CTSV | O60911 | 1/20 | 0.45 |
| ▸ | CTSL | P07711 | 1/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | GSK3B | P49841 | 1/20 | 0.44 |
| ▸ | MGAM | O43451 | 1/20 | 0.42 |
| ▸ | SI | P14410 | 1/20 | 0.42 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26993708 | 0.77 | KDM4E (0.63) | KDM4EALDH1A1HPGDHSD17B10GAA | |
| SCHEMBL16237897 | 0.77 | KDM4E (0.63) | KDM4EALDH1A1HPGDHSD17B10GAA | |
| SCHEMBL301567 | 0.77 | KDM4E (0.63) | KDM4EALDH1A1HPGDHSD17B10GAA | |
| SCHEMBL130919 | 0.77 | KDM4E (0.63) | KDM4EALDH1A1HPGDHSD17B10GAA | |
| SCHEMBL29365383 | 0.77 | KDM4E (0.63) | KDM4EALDH1A1HPGDHSD17B10GAA | |
| Acridone SCHEMBL28159674 | 0.76 | KDM4E (0.69) | KDM4EALDH1A1HPGDHSD17B10GAA | |
| SCHEMBL170077 | 0.75 | KDM4E (0.62) | KDM4EALDH1A1HPGDHSD17B10GAA | |
| SCHEMBL16254241 | 0.75 | CTSV (0.59) | KDM4EALDH1A1HPGDHSD17B10GAA | |
| SCHEMBL28262029 | 0.75 | ALDH1A1 (0.41) | KDM4EALDH1A1HPGDHSD17B10GAA | |
| SCHEMBL16254239 | 0.74 | ALDH1A1 (0.55) | KDM4EALDH1A1HPGDHSD17B10GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160131648-A1 | ALKYL QUINOLONES AS BIOMARKERS OF PSEUDOMONAS AERUGINOSA INFECTION AND USES THEREOF | THE UNIVERSITY OF NOTTINGHAM (GB) | 2016-05-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160131648-A1 | ALKYL QUINOLONES AS BIOMARKERS OF PSEUDOMONAS AERUGINOSA INFECTION AND USES THEREOF | NQO2, QARS1, CD14 | KDM4E 4049/4885ALDH1A1 1222/4885HPGD 126/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.